TABLE 1

Changes from baseline at 6 and 12 months, and 2 years after coil treatment

Overall groupPatients who attended the 2-year follow-up visit
Baseline6 months12 monthsBaseline6 months12 months2 years
Subjects n50474432323232
6MWT m300±112+18±81; p=0.14−2±87; p=0.88323±105+25±67; p=0.048+15±77; p=0.29+6±84; p=0.56
 ≥54 m16/44 (36%)8/43 (19%)12/32 (38%)7/32 (22%)7/28 (25%)
 ≥25 m19/44 (43%)12/43 (28%)15/32 (47%)11/32 (34%)11/28 (39%)
mMRC scale3±0.7−0.5±0.9; p=0.0002−0.5±1; p=0.0062.9±0.6−0.7±0.9; p=0.0003−0.7±1; p=0.0007−0.4±1; p=0.06
≥119/47 (40%)19/41 (46%)15/32 (47%)15/30 (50%)13/30 (43%)
FEV1 L0.75±0.25+0.05±0.14; p=0.02+0.04±0.15; p=0.10.78±0.26+0.04±0.15; p=0.15+0.03±0.14; p=0.210±0.16; p=0.92
 ≥100 mL17/47 (36%)12/44 (27%)12/32 (38%)8/32 (25%)8/32 (25%)
 ≥10%21/47 (45%)14/44 (32%)14/32 (44%)9/32 (28%)12/32 (38%)
RV L6.2±0.86−0.53±0.72; p<0.0001−0.47±0.68; p<0.00015.92±0.74−0.46±0.51; p<0.0001−0.39±0.68; p=0.003−0.28±0.69; p=0.03
≥350 mL29/47 (62%)25/44 (57%)19/32 (59%)18/32 (56%)14/32 (44%)
SGRQ (0–100)60.8±12.8−11.1±16.1; p<0.0001−9.1±15.9; p=0.000657.9±12.3−12.3±17.6; p=0.0005−11.5±16.4; p=0.0006−7.9±14.5; p=0.005
 ≥4 points32/45 (71%)26/42 (62%)24/31 (77%)21/30 (70%)20/31 (65%)
 ≥8 points28/45 (62%)21/42 (50%)21/31 (68%)16/30 (53%)16/31 (52%)

Data are presented as mean±sd or number (%), unless otherwise stated. The percentage of patients reaching the minimal clinically important difference for each variable is indicated. Changes from baseline were assessed by paired t-tests. 6MWT: 6-min walking test; mMRC : modified Medical Research Council dyspnoea scale; FEV1: forced expiratory volume 1 s; RV: residual volume; SGRQ: Saint George's Respiratory Questionnaire.